It is well known that the PI3K/Akt/mTOR pathway contributes to Gemcitabine resistance in pancreatic cancer, and the dysregulation of this pathway is frequently observed in pancreatic cancer. The gene discussed is AKT1; the disease is familial pancreatic carcinoma.